RT Journal Article SR Electronic T1 â–¼Naltrexone/bupropion for obesity JF Drug and Therapeutics Bulletin JO Drug Ther Bull FD BMJ Publishing Group Ltd SP 126 OP 129 DO 10.1136/dtb.2017.11.0550 VO 55 IS 11 YR 2017 UL http://dtb.bmj.com/content/55/11/126.abstract AB â–¼ Naltrexone/bupropion (Mysimba - Orexigen Therapeutics Ireland Limited) is a fixed-dose combination product for the treatment of adults who are obese or overweight with at least one weight-related comorbidity, as an adjunct to diet and lifestyle modifications. Originally licensed by the European Medicines Agency (EMA) in 2015, it has recently been launched in the UK. Here, we review the evidence for its efficacy and safety and consider its place in therapy.